306 related articles for article (PubMed ID: 25985814)
1. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.
Rogala B; Freyer CW; Ontiveros EP; Griffiths EA; Wang ES; Wetzler M
Expert Opin Biol Ther; 2015 Jun; 15(6):895-908. PubMed ID: 25985814
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
3. Blinatumomab for the treatment of B-cell lymphoma.
Oak E; Bartlett NL
Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
[TBL] [Abstract][Full Text] [Related]
4. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Bumma N; Papadantonakis N; Advani AS
Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
6. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
7. Blinatumomab for the treatment of acute lymphoblastic leukemia.
Kaplan JB; Grischenko M; Giles FJ
Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
9. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
10. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
Dahl J; Mace M; Kantarjian H; Jabbour E
Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
[TBL] [Abstract][Full Text] [Related]
11. A review of blinatumomab, a novel immunotherapy.
Newman MJ; Benani DJ
J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
[TBL] [Abstract][Full Text] [Related]
12. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Hays P
Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
[TBL] [Abstract][Full Text] [Related]
13. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
14. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies.
Burt R; Warcel D; Fielding AK
Hum Vaccin Immunother; 2019; 15(3):594-602. PubMed ID: 30380973
[TBL] [Abstract][Full Text] [Related]
15. Targeting non-Hodgkin lymphoma with blinatumomab.
Sanders S; Stewart DA
Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
Wilke AC; Gökbuget N
Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
[TBL] [Abstract][Full Text] [Related]
17. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
18. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
19. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
[TBL] [Abstract][Full Text] [Related]
20. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
